Zacks Research Issues Optimistic Estimate for IRWD Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Analysts at Zacks Research increased their FY2026 earnings per share (EPS) estimates for Ironwood Pharmaceuticals in a research note issued on Wednesday, January 8th. Zacks Research analyst R. Department now forecasts that the biotechnology company will earn $0.44 per share for the year, up from their previous forecast of $0.43. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.08 per share.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business had revenue of $91.60 million during the quarter, compared to analysts’ expectations of $91.22 million. During the same period in the prior year, the firm posted $0.12 EPS. The firm’s revenue for the quarter was down 19.4% on a year-over-year basis.

Separately, StockNews.com cut shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.40.

Ironwood Pharmaceuticals Stock Performance

IRWD opened at $3.96 on Monday. Ironwood Pharmaceuticals has a fifty-two week low of $3.06 and a fifty-two week high of $15.70. The firm has a 50-day moving average of $4.06 and a 200 day moving average of $4.73. The firm has a market cap of $633.71 million, a P/E ratio of -132.00 and a beta of 0.34.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in IRWD. KBC Group NV boosted its position in shares of Ironwood Pharmaceuticals by 59.3% in the third quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 3,198 shares during the period. Wolverine Trading LLC purchased a new stake in Ironwood Pharmaceuticals in the 3rd quarter worth approximately $51,000. Diversified Trust Co bought a new position in Ironwood Pharmaceuticals in the 3rd quarter valued at $52,000. Legacy Capital Group California Inc. purchased a new position in shares of Ironwood Pharmaceuticals during the 3rd quarter valued at $59,000. Finally, Virtu Financial LLC purchased a new position in shares of Ironwood Pharmaceuticals during the 3rd quarter valued at $78,000.

Insiders Place Their Bets

In other news, CFO Sravan Kumar Emany sold 11,001 shares of Ironwood Pharmaceuticals stock in a transaction on Monday, November 18th. The stock was sold at an average price of $4.08, for a total value of $44,884.08. Following the completion of the transaction, the chief financial officer now directly owns 309,572 shares in the company, valued at approximately $1,263,053.76. The trade was a 3.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 12.90% of the company’s stock.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.